Your shopping cart is currently empty

ETTAC-2 is an LRG1 PROTAC degrader that facilitates the ubiquitination and degradation of LRG1, with a DC50 of 8.38 µM. It inhibits the TGF-β-Smad3 signaling pathway and reduces the secretion of proteins associated with fibrosis. ETTAC-2 can slow the progression of renal fibrosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | ETTAC-2 is an LRG1 PROTAC degrader that facilitates the ubiquitination and degradation of LRG1, with a DC50 of 8.38 µM. It inhibits the TGF-β-Smad3 signaling pathway and reduces the secretion of proteins associated with fibrosis. ETTAC-2 can slow the progression of renal fibrosis. |
| Molecular Weight | 1891.07 |
| Formula | C83H123N23O26S |
| Smiles | CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)CNC(=O)CCC(=O)NC3=CC=CC4=C3CN(C4=O)C5CCC(=O)NC5=O |
| Sequence | Lenalidomide-(CC)-Gly-Gly-Glu-Ser-Tyr-Ser-Ala-Lys-His-Arg-Ile-Met-Leu-Thr |
| Sequence Short | Lenalidomide-(CC)-GGESYSAKHRIMLT |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.